ABBOTT LABS shareholders Q3 2023

ABBOTT LABS's ticker is ABT and the CUSIP is 002824100. A total of 2,612 filers reported holding ABBOTT LABS in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.

ABBOTT LABS shareholders Q3 2023
NameSharesValueWeighting ↓
Miramar Capital, LLC 114,777$11,116,1493.02%
MONTAG & CALDWELL, LLC 242,013$23,438,9593.01%
Dempze Nancy E 34,320$3,323,8922.98%
PRENTISS SMITH & CO INC 41,801$4,048,4272.98%
First Long Island Investors, LLC 317,693$30,768,5672.98%
PUZO MICHAEL J 90,505$8,765,4092.97%
HOMESTEAD ADVISERS CORP 1,101,146$106,645,9902.96%
Cornerstone Capital, Inc. 252,816$24,485,2302.95%
ABSHER WEALTH MANAGEMENT, LLC 182,867$17,710,7562.95%
HARVEY INVESTMENT CO LLC 230,195$22,2942.92%
M. Kraus & Co 84,541$8,187,8262.91%
SIRIOS CAPITAL MANAGEMENT L P 158,269$15,328,3532.90%
BROOKS, MOORE & ASSOCIATES, INC. 39,645$3,8402.90%
Silver Lake Advisory, LLC 48,376$4,6852.89%
DAVIDSON TRUST CO 39,924$3,866,6392.87%
Cox Capital Mgt LLC 42,049$4,072,4272.86%
Apeiron RIA LLC 86,697$8,396,6042.86%
Providence Capital Advisors, LLC 112,852$10,929,7382.86%
PHILADELPHIA TRUST CO 284,764$27,5792.83%
MARK SHEPTOFF FINANCIAL PLANNING, LLC 45,452$4,402,0142.82%
About ABBOTT LABS

Abbott Labs: A Leading Healthcare Company

Abbott Labs is a global healthcare company that specializes in the development and manufacturing of medical devices, diagnostics, and pharmaceuticals. The company has a strong presence in more than 160 countries and has been in operation for over 130 years.

Abbott Labs has a diverse portfolio of products that cater to various healthcare needs. The company's medical devices range from cardiovascular and diabetes care to neuromodulation and vision care. Abbott Labs also has a strong presence in the diagnostics market, with a focus on infectious diseases, oncology, and genetics. The company's pharmaceuticals division focuses on developing drugs for various therapeutic areas, including immunology, oncology, and neuroscience.

Abbott Labs has a strong leadership team, with Robert B. Ford serving as the company's CEO and Chairman of the Board. Under his leadership, the company has continued to grow and expand its product portfolio. In 2020, Abbott Labs received emergency use authorization from the FDA for its COVID-19 rapid test, which has been instrumental in the fight against the pandemic.

In conclusion, Abbott Labs is a leading healthcare company with a diverse portfolio of products and a strong global presence. The company's commitment to innovation and its focus on meeting the healthcare needs of people around the world make it a valuable investment for stock market investors.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists ABBOTT LABS's shareholders in Q3 2023. To view ABBOTT LABS's shareholder history, click here.